Department of Medicine

Endocrinology, Diabetes and Metabolism Research

RESEARCH SUMMARY

Our group also conducts clinical/translational research at outpatient clinics and inpatient service sites within the University of Toledo Health Sciences Campus (UT Medical Center, Ruppert Health Center, Dana Cancer Center) and the ProMedica Health Campus (The Toledo Hospital and the Falzone Diabetes Center).  Basic sciences research is conducted at the Center for Diabetes and Endocrine Research (CeDER) at the UT Health Sciences Campus. 

Scientifically, the Division’s research encompasses clinical, translational and basic science areas as described below:

 Current Clinical/Translational projects include:

  1. Latent Autoimmune Diabetes of Adult Database Study (IRB approved)
  2. Anti-Program Cell Death-1 Pathway Blockade and Type 1 Diabetes Development (MEDTRONIC GRANT AWARD) (IRB approved)
  3. Calcitonin Enhanced Localization of Parathyroid Adenomas (IRB approved)
  4. Thyroid Nodule Database Study (IRB approved)
  5. Insulin Antibodies and Insulin Resistance (IRB approved)
  6. Glycemic Control with Digitally Coordinated Care in Type II Diabetic Populations (IRB approved)
  7. Low Dose CT and Adrenal Incidentalomas (IRB approved)
  8. SGLT2 Protracted Glycosuria (IRB pending)
  9. New Onset Diabetes After Transplant (NODAT, IRB pending)
  10. Glycemic variability during enteral nutrition (IRB pending)

Current Basic/Translational projects include:

  1. Characterization of a New Humanized Transgenic Model of Type 1 Diabetes (US Patent filed)
  2. Experimental Immunotherapeutic Approaches for Treatment of Type 1 Diabetes (US Patent filed)
  3. Thyroid Cancer Cellular Biomarkers (US Patent filed)
  4. Tumor Immunity Induction Studies

For details on Division’s basic sciences research program go to:

Center for Diabetes and Endocrine Research (CeDER)

LabS WebsiteS

JUAN C. JAUME LAB

JOHN JUN LAB

Recent /relevant peer reviewed abstracts/papers (2015 to present)

  1. J. B. Hao, A. Schuna and J. C. Jaume. Extree Insulin Resistance from Insulin Antibodies (not Insulin Receptor Antibodies) Successfully Treated with Combination Immunosuppresive Therapy.  The Endocrine Society.  San Diego, CA 2015.
  2. S. Imam, R. Paparodis and J. C. Jaume.  Does Macrophage Plasticity in Thyroid Microenvironment Decide the Fate of Thyroid cancer?  The Endocrine Society.  San Diego, CA 2015.
  3. R. Paparodis R and J. C. Jaume.  Reanalysis of the data reveal even stronger associations between Hashimoto's thyroiditis and differentiated thyroid cancer.  Thyroid. 2015;25:142
  4. J. B. Hao, S Thida, S Sirinvaravong, A Day and J. C. Jaume*.  Early Adulthood Onset Diabetes: T1DM, T2DM, Latent Autoimmune Diabetes of Adults, does it really matter?  The Endocrine Society.  Boston, MA 2016.  *Helmsley Charitable Abstract Award in T1D
  5. A. Renno, J.B. Hao, S. Imam, J.C. Jaume.  An FDA Approve Drug that Causes Type 1 Diabetes.  Is it Just Coincidence?  The Endocrine Society.  Boston, MA 2016.
  6. J. B. Hao, A. Renno, S. Imam, M. A. Alfonso-Jaume, N. Elnagar and J. C. Jaume.  Development of Type 1 Diabetes after Cancer Immunotherapy.  Endocr Pract Epub 2016.
  7. J. B. Hao, S. Imam, P. Dar, M. A. Alfonso-Jaume, N. Elnagar and J. C. Jaume.  Extreme Insulin Resistance from Insulin Antibodies (Not Insulin Receptor Antibodies) Succesfully Treated with Combination Immunosuppressive Therapy. Diabetes Care Epub 2016.
  8. R.D. Paparodis, D. Bantouna, S. Imam and J.C. Jaume. The Risk of Thyroid Cancer Depends on the Type of Autoimmune Thyroid Disease Associated with It.  The Endocrine Society.  Orlando, FL 2017.
  9. G. Antoniou, S. Kasikis, C. Chourpiliadis, D. Bantouna, J.C. Jaume and R.D. Paparodis.  Patients with History of Fractures Have Profound Abnormalities in Bone Metabolism and Thyroid Function.  The Endocrine Society.  Orlando, FL 2017.
  10. R.D. Paparodis, D. Bantouna, S. Imam and J.C. Jaume. Higher Serum TSH Is Associated with Differentiated Thyroid Cancer Risk, Only in the Absence of Thyroid Autoimmunity. The Endocrine Society.  Orlando, FL 2017.
  11. S. Imam, P Dar, K. Almotah, R.D. Paparodis and J.C. Jaume.  Macrophage-Natural Killer Cell Cross-Talk: Implications for Thyroid Cancer.  The Endocrine Society.  Orlando, FL 2017.
  12. R.D. Paparodis, D. Bantouna, S. Imam and J.C. Jaume. Comparison of Features of Tumor Aggressiveness Between Thyroid Papillary Microcarcinomas and Macrocarcinomas.  The Endocrine Society.  Orlando, FL 2017.
  13. G. Antoniou, S. Kasikis, C. Chourpiliadis, D. Bantouna, J.C. Jaume and R.D. Paparodis.  Biochemically Euthyroid Patients with Symptoms Attributable to Thyroid Disease, Have a High Prevalence of Abnormal Bone Density and Fractures.  The Endocrine Society.  Orlando, FL 2017. 
  14. M.S. Khan, J.B. Hao, F. Chaudhry, A. Tiwari, H. Sharma and J.C. Jaume.  Response to IVIG Leads to Diagnosis of Stiff Person Syndrome in a Patient with Limbic Encephalitis and GAD65 Autoantibodies without Diabetes.  The Endocrine Society.  Orlando, FL 2017.
  15. J. B. Hao, S. Imam, P. Dar, M. A. Alfonso-Jaume, N. Elnagar and J. C. Jaume.  Extreme Insulin Resistance from Insulin Antibodies (Not Insulin Receptor Antibodies) Successfully Treated with Combination Immunosuppressive Therapy.  Diabetes Care. 2017 Feb;40(2):e19-e20 
  16. I.A. Hajam, P.A. Dar, S, Imam, J.C. Jaume JC and J.H. Lee.  Bacterial flagellin-a potent immunomodulatory agent.  Exp Mol Med. 2017 Sep 1;49(9):e373
  17. J. B. Hao, A. Renno, S. Imam, M. A. Alfonso-Jaume, N. Elnagar and J. C. Jaume.  Development of Type 1 Diabetes after Cancer Immunotherapy.  Endocr Pract Epub 2017 
  18. O. Oraibi, L.I. Wharry, A.A. Lynn, F. Chaudhry, J.C. Jaume, J.Y. Jun.  A Case of Adrenal Malignant Pheochromocytoma Combined with Primary Malignant Lymphoma. The Endocrine Society.  Chicago, IL 2018
  19. S. Imam, K.I. Almotah, P. Dar, A.S. AlKhudhair, R. Lamendella, J.C. Jaume.  Prolonged Nursing (late Weaning), Delays The Onset Of Type 1 Diabetes In The Genetic Susceptible Humanized Mouse Model Of T1D.  The Endocrine Society.  Chicago, IL 2018
  20. C.P. Chourpiliadis, G. Antoniou, S. Kasikis, P-C.P. Koukoutsidi, L-N. Diamantopoulos, D. Bantouna, J.C. Jaume, R. Paparodis.  Fractures of Any Kind, at Any Age Predict Low Bone Mineral Density and Osteoporosis. The Endocrine Society.  Chicago, IL 2018
  21. S. Alhassan, M. Rudoni, J.C. Jaume.  Prolonged Glucosuria After Discontinuation Sglt2 Inhibitors: Implications For Weekly Dosing And Extended Risk Of Euglycemic Diabetes Keto-acidosis.  The Endocrine Society.  Chicago, IL 2018
  22. R. Paparodis, D. Bantouna, S. Imam, J.C. Jaume. The Impact of Follicular Variant Papillary Thyroid Cancer (FV-PTC) in Features of Tumor Aggressiveness in Thyroid Papillary Microcarcinomas and Macrocarcinomas.  The Endocrine Society.  Chicago, IL 2018
  23. S. Kasikis, G. Antoniou, P-C. P. Koukoutsidi, C.P. Chourpiliadis, D. Bantouna, M. Panagiota, J.C. Jaume, R. Paparodis.  Bone Mineral Density Abnormalities in Patients with Biochemically Euthyroid Thyroiditis.  The Endocrine Society.  Chicago, IL 2018
  24. A. Tiwari, H. Al-Robeh, H Sharma, Z. Ammari, M. Saud Khan, J. C. Jaume.  Steroid-induced diabetic ketoacidosis in patient with type 2 diabetes mellitus. Endocr Pract Epub 2018
  25. Ammari Z, Pak SC, Ruzieh M, Dasa O, Tiwari A, Jaume JC, Alfonso-Jaume MA.  Posttransplant Tacrolimus-Induced Diabetic Ketoacidosis: Review of the Literature. Case Rep Endocrinol. 2018 May 9;2018:4606491.
  26. Imam S, Dar P, Paparodis R, Almotah K, Al-Khudhair A, Hasan SA, Salim N, Jaume JC.  Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer.  J Immunother Cancer. 2019 Jan 7;7(1):3.
  27. Imam S, Prathibha R, Dar P, Almotah K, Al-Khudhair A, Hasan SA, Salim N, Jilani TN, Mirmira RG, Jaume JC.  eIF5A inhibition influences T cell dynamics in the pancreatic microenvironment of the humanized mouse model of Type 1 Diabetes.  Sci Rep. 2019 Feb 7;9(1):1533.
  28. Paparodis RD, Bantouna D, Imam S, Jaume JC.  The non-interventional approach to papillary thyroid microcarcinomas. An "active surveillance" dilemma.  Surg Oncol. 2019 Jun;29:113-117.
  29. Pappada SM, Owais MH, Cameron BD, Jaume JC, Mavarez-Martinez A, Tripathi RS, Papadimos TJ.  An Artificial Neural Network-based Predictive Model to Support Optimization of Inpatient Glycemic Control.  Diabetes Technol Ther. 2020 Feb 6. doi: 10.1089/dia.2019.0252. [Epub ahead of print].
  30. Paparodis RD, Karvounis E, Bantouna D, Chourpiliadis C, Chourpiliadi H, Livadas S, Imam S, Jaume JC.  Incidentally Discovered Papillary Thyroid Microcarcinomas Are More Frequently Found in Patients with Chronic Lymphocytic Thyroiditis Than with Multinodular Goiter or Graves' Disease.  Thyroid. 2020 Feb 20. doi: 10.1089/thy.2019.0347. [Epub ahead of print]

 Book Chapters

  1. J.C. Jaume.  Endocrine autoimmunity.  In Greenspan’s Basic & Clinical Endocrinology.  10th ed. Gardner DG and Shoback DM, Eds. McGraw-Hill Medical, 2017, Chapter 2; pages 29-48 (Last 6 editions).
  2. H. Chen, D.F. Schneider, H. Mazeh, J.C. Jaume, S. Lubner.  Cancer of the Endocrine System.  In Abeloff’s Clinical Oncology.  5th ed. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB and McKenna WG, Eds.  Churchill Livingstone Elsevier, 2013, Chapter 71, pages 1112-1142.
  3. N. Elnagar, S. Alhassan, F. Khogeer, J. Jun, F. Chaudhry, M. Alfonso-Jaume, J.C. Jaume.  The Noha (nəʊ ˈhaʊ) Manual of Inpatient Diabetes Management.  Kindle Direct Publishing -Amazon.com, 2018. 

emanual cover        

REQUEST ORDERSET 

Give Now                                                                                       

 Fund # 2402325

Last Updated: 3/9/20